A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1519-1531

  Lee, Cheng Han ^a   Turbin, Dmitry A ^a   Sung, Y C Vanessa ^a   Espinosa, Inigo ^b   Montgomery, Kelli ^c   Van De Rijn, Matt ^c   Gilks, C Blake ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ER; Ki 67; Leiomyosarcoma; P16; P53; Uterine leiomyoma

Indexed keywords

ANTIBODY; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; WT1 PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER SURVIVAL; DIFFERENTIAL DIAGNOSIS; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

EID: 71149108700     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.122     Document Type: Article

References (41)

1. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology 2006;48:97-105.
2. Giuntoli 2nd RL, Bristow RE. Uterine leiomyosarcoma: present management. Curr Opin Oncol (2004) 16, 324-327.
3. Mankin HJ, Hornicek FJ. Diagnosis, classification, and management of soft tissue sarcomas. Cancer Control 2005;12:5-21.
4. Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinico-pathologic study. Gynecol Oncol 2005;99:36-42.
5. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Antic-ancer Res 2003;23:729-732. (Pubitemid 36358480)
6. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004;81:1062-1066.
7. Gokaslan H, Turkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005;59:36-40.
8. Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extra-uterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 2004;12: 338-341.
9. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101: 1455-1462.
10. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 1999;12:1001-1009.
11. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyo-sarcomas. Int J Gynecol Pathol 1999;18:20-28.
12. Jakimiuk AJ, Bogusiewicz M, Tarkowski R, et al. Estrogen receptor alpha and beta expression in uterine leiomyomas from premenopausal women. Fertil Steril 2004;82:1244-1249.
13. Bing Z, Pasha TL, Acs G, et al. Cytoplasmic over-expression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors. Appl Immunohistochem Mol Morphol 2008;16:316-321.
14. Coosemans A, Nik SA, Caluwaerts S, et al. Upregula-tion of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 2007;43:1630-1637.
15. Deavers MT. Immunohistochemistry in gynecologic pathology. Arch Pathol Lab Med 2008;132:175-180.
16. Giuntoli 2nd RL, Gostout BS, DiMarco CS, et al. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007;52:1001-1010.
17. Atkins KA, Arronte N, Darus CJ, et al. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 2008;32: 98-102.
18. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005;96:62-66.
19. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008;27:326-332.
20. Gannon BR, Manduch M, Childs TJ. Differential immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Int J Gynecol Pathol 2008;27: 68-73.
21. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol 1997;65: 330-335.
22. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand 2004;83: 1085-1088.
23. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32: 984-987.
24. Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosar-comas. Clin Cancer Res 2008;14:1423-1430.
25. Espinosa I, Beck AH, Lee CH, et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 2009;174:2347-2356.
26. Steigen SE, Straume B, Turbin D, et al. Clinicopatho-logic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stro-mal tumors. J Histochem Cytochem 2008;56:139-145.
27. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol 1995;14:134-142.
28. Chou CY, Huang SC, Tsai YC, et al. Uterine leiomyo-sarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol Oncol 1997;65:225-231.
29. Jeffers MD, Oakes SJ, Richmond JA, et al. Proliferation, ploidy and prognosis in uterine smooth muscle tumours. Histopathology 1996;29:217-223.
30. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol Oncol 2004;92: 175-179.
31. O'Neill CJ, McBride HA, Connolly LE, et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histo-pathology 2007;50:851-858.
32. O'Reilly PE, Raab SS, Niemann TH, et al. p53, proliferating cell nuclear antigen, and Ki-67 expression in extra-uterine leiomyosarcomas. Mod Pathol 1997;10:91-97.
33. Deavers MT, Silva EG, Euscher ED, et al. WT1 expression may differentiate mullerian from non-mullerian smooth muscle tumors. Mod Pathol 2006;19:176A.
34. Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gyne-col Cancer 2006;16:849-853.
35. Blom R, Guerrieri C, Stal O, et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54-61. (Pubitemid 28109824)
36. de Vos S, Wilczynski SP, Fleischhacker M, et al. p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 1994;54:205-208.
37. Layfield LJ, Liu K, Dodge R, et al. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histo-pathology. Arch Pathol Lab Med 2000;124:221-227.
38. Niemann TH, Raab SS, Lenel JC, et al. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 1995;26:375-379.
39. Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol 2009;33:992-1005.
40. Agoff SN, Grieco VS, Garcia R, Gown AM. Immunohistochemical distinction of endometrial stro-mal sarcoma and cellular leiomyoma. Appl Immuno-histochem Mol Morphol 2001;9:164-169.
41. Konomoto T, Fukuda T, Hayashi K, et al. Leiomyosar-coma in soft tissue: examination of p53 status and cell proliferating factors in different locations. Hum Pathol 1998;29:74-81.